409 related articles for article (PubMed ID: 11833835)
21. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in percutaneous peripheral intervention: a single-center experience.
Sheikh IR; Ahmed SH; Mori N; Gupta A; Mewissen M; Allaqaband S; Bajwa T
JACC Cardiovasc Interv; 2009 Sep; 2(9):871-6. PubMed ID: 19778776
[TBL] [Abstract][Full Text] [Related]
22. The use of bivalirudin in patients with renal impairment.
Robson R
J Invasive Cardiol; 2000 Dec; 12 Suppl F():33F-6. PubMed ID: 11156732
[TBL] [Abstract][Full Text] [Related]
23. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
[TBL] [Abstract][Full Text] [Related]
24. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G
Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760
[TBL] [Abstract][Full Text] [Related]
25. Bivalirudin: a review of the pharmacology and clinical application.
Van De Car DA; Rao SV; Ohman EM
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1673-81. PubMed ID: 21108549
[TBL] [Abstract][Full Text] [Related]
26. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin.
Bates SM; Weitz JI
Am J Cardiol; 1998 Oct; 82(8B):12P-18P. PubMed ID: 9809887
[TBL] [Abstract][Full Text] [Related]
27. Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes.
Bates ER
Curr Cardiol Rep; 2001 Sep; 3(5):348-54. PubMed ID: 11504570
[TBL] [Abstract][Full Text] [Related]
28. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.
Direct Thrombin Inhibitor Trialists' Collaborative Group
Lancet; 2002 Jan; 359(9303):294-302. PubMed ID: 11830196
[TBL] [Abstract][Full Text] [Related]
29. Clinical applications of bivalirudin in the cardiac catheterization laboratory.
Thompson KA; Philip KJ; Schwarz ER
J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):140-9. PubMed ID: 21097669
[TBL] [Abstract][Full Text] [Related]
30. Bivalirudin in percutaneous coronary intervention, is it the anticoagulant of choice?
Mahmoud A; Saad M; Elgendy AY; Abuzaid A; Elgendy IY
Cardiovasc Ther; 2015 Aug; 33(4):227-35. PubMed ID: 25879426
[TBL] [Abstract][Full Text] [Related]
31. Bivalirudin.
Warkentin TE; Greinacher A; Koster A
Thromb Haemost; 2008 May; 99(5):830-9. PubMed ID: 18449412
[TBL] [Abstract][Full Text] [Related]
32. Bivalirudin: a new generation antithrombotic drug.
Scatena R
Expert Opin Investig Drugs; 2000 May; 9(5):1119-27. PubMed ID: 11060732
[TBL] [Abstract][Full Text] [Related]
33. Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction.
French JK; Edmond JJ; Gao W; White HD; Eikelboom JW
Am J Cardiovasc Drugs; 2004; 4(2):107-15. PubMed ID: 15049722
[TBL] [Abstract][Full Text] [Related]
34. Safety of bivalirudin in patients with coronary artery disease.
Abdel-Wahab M; Richardt G
Expert Opin Drug Saf; 2012 Jan; 11(1):141-50. PubMed ID: 21999110
[TBL] [Abstract][Full Text] [Related]
35. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial).
Lincoff AM; Bittl JA; Kleiman NS; Sarembock IJ; Jackman JD; Mehta S; Tannenbaum MA; Niederman AL; Bachinsky WB; Tift-Mann J; Parker HG; Kereiakes DJ; Harrington RA; Feit F; Maierson ES; Chew DP; Topol EJ;
Am J Cardiol; 2004 May; 93(9):1092-6. PubMed ID: 15110198
[TBL] [Abstract][Full Text] [Related]
36. Bivalirudin: in patients with acute coronary syndromes : planned for urgent or early intervention.
Deeks ED; Curran MP
Drugs; 2008; 68(16):2345-56. PubMed ID: 18973397
[TBL] [Abstract][Full Text] [Related]
37. Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States.
Secemsky EA; Kirtane A; Bangalore S; Jovin IS; Shah RM; Ferro EG; Wimmer NJ; Roe M; Dai D; Mauri L; Yeh RW
JACC Cardiovasc Interv; 2016 Dec; 9(23):2376-2386. PubMed ID: 27838271
[TBL] [Abstract][Full Text] [Related]
38. FDA panel votes against approval for bivalirudin.
Piña I
Circulation; 1999 Mar; 99(10):1277. PubMed ID: 10077507
[No Abstract] [Full Text] [Related]
39. Bivalirudin for patients with acute coronary syndromes.
Stone GW; McLaurin BT; Cox DA; Bertrand ME; Lincoff AM; Moses JW; White HD; Pocock SJ; Ware JH; Feit F; Colombo A; Aylward PE; Cequier AR; Darius H; Desmet W; Ebrahimi R; Hamon M; Rasmussen LH; Rupprecht HJ; Hoekstra J; Mehran R; Ohman EM;
N Engl J Med; 2006 Nov; 355(21):2203-16. PubMed ID: 17124018
[TBL] [Abstract][Full Text] [Related]
40. Bivalirudin: a review.
Warkentin TE; Koster A
Expert Opin Pharmacother; 2005 Jul; 6(8):1349-71. PubMed ID: 16013985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
